NASDAQ:SGHT Sight Sciences Q2 2025 Earnings Report $3.41 -0.02 (-0.58%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.41 0.00 (0.00%) As of 07/11/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Sight Sciences EPS ResultsActual EPSN/AConsensus EPS -$0.25Beat/MissN/AOne Year Ago EPSN/ASight Sciences Revenue ResultsActual RevenueN/AExpected Revenue$18.18 millionBeat/MissN/AYoY Revenue GrowthN/ASight Sciences Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, July 31, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Sight Sciences Earnings HeadlinesSight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi Sells 23,637 SharesJuly 9, 2025 | americanbankingnews.comSGHT - Sight Sciences Inc Chart - MorningstarJuly 5, 2025 | morningstar.comMPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors. | Paradigm Press (Ad)Sight Sciences Leads The Pack Of 3 Promising Penny StocksJune 24, 2025 | uk.finance.yahoo.comsight sciences appoints new board member and holds annual meetingJune 7, 2025 | uk.investing.comSight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27thMay 14, 2025 | globenewswire.comSee More Sight Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sight Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sight Sciences and other key companies, straight to your email. Email Address About Sight SciencesSight Sciences (NASDAQ:SGHT) is an ophthalmic medical device company focused on developing innovative technologies to diagnose and treat eye conditions. Since its founding in 2011, the company has concentrated on ophthalmic solutions for ocular surface disease and glaucoma, combining engineering expertise with clinical research to address unmet needs in eye care. The company’s flagship product, the TearCare® System, is designed to treat Meibomian Gland Dysfunction (MGD), a leading cause of evaporative dry eye disease. The system delivers controlled thermal energy to the eyelids and simultaneously applies natural gland expression, helping to restore gland function and improve tear film quality. In parallel, Sight Sciences is advancing a pipeline of diagnostic and therapeutic devices aimed at better managing glaucoma and other anterior segment disorders. Headquartered in Menlo Park, California, Sight Sciences has established a U.S. commercial footprint and is pursuing international distribution through strategic partnerships. The company supports eye care professionals with training programs, clinical support, and ongoing education to facilitate the adoption of its technologies and to ensure optimal patient outcomes. Under the leadership of Chief Executive Officer Keith Walter and a management team with extensive experience in ophthalmology and medical technology, Sight Sciences remains committed to driving clinical evidence and expanding its product portfolio. The company continues to invest in research and development, leveraging data from multicenter trials to advance its mission of improving the quality of life for patients with eye disease.Written by Jeffrey Neal JohnsonView Sight Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
